NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Incyte Corporation
AstraZeneca
Eli Lilly and Company
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.